57961-49-6

Basic information

• Product Name: ETHYL 4-(3-NITROPHENYL)-2,4-DIOXOBUTANOATE
• Synonyms: ETHYL 4-(3-NITROPHENYL)-2,4-DIOXOBUTANOATE
• CAS NO: 57961-49-6
• Molecular Formula: C₁₂H₁₁NO₆
• Molecular Weight: 265.22
• Mol File: 57961-49-6.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ETHYL 4-(3-NITROPHENYL)-2,4-DIOXOBUTANOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 4-(3-NITROPHENYL)-2,4-DIOXOBUTANOATE(57961-49-6)
• EPA Substance Registry System: ETHYL 4-(3-NITROPHENYL)-2,4-DIOXOBUTANOATE(57961-49-6)

Safety Data

• Hazardous Substances Data: 57961-49-6(Hazardous Substances Data)

Upstream product

• 95-92-1 oxalic acid diethyl ester 
• 121-89-1 3-Nitroacetophenone 

Downstream Products

• 1025724-57-5 ethyl 3-(3-nitrophenyl)-1H-pyrazole-5-carboxylate 
• 199601-80-4 5-(3-nitrophenyl)-isoxazole-3-carboxylic acid 
• 1446419-19-7 C₁₄H₁₆N₄O₆ 
• 1446419-18-6 C₁₄H₁₆N₄O₅ 
• 1446419-17-5 C₁₃H₁₄N₄O₄ 
• 1446450-03-8 C₁₃H₁₄N₄O₄ 
• 1446419-16-4 C₁₃H₁₄N₄O₄ 
• 1446419-15-3 C₁₄H₁₆N₄O₅ 
• 1446419-14-2 C₁₂H₁₂N₄O₄ 
• 1048938-41-5 N'-[(2-hydroxynaphthalen-1-yl)methylene]-5-(3-nitrophenyl)-1H-pyrazole-3-carbohydrazone 
• 307349-77-5 5-(3-nitrophenyl)-1H-pyrazole-3-carbohydrazide 
• 1025724-57-5 ethyl 5-(3-nitrophenyl)-1H-pyrazole-3-carboxylate 
• 1316754-45-6 C₂₃H₂₆N₆O₃ 
• 899714-76-2 C₁₀H₇N₃O₄ 

Relevant articles and documents

Novel N-benzylpiperidine derivatives of 5-arylisoxazole-3-carboxamides as anti-Alzheimer's agents

The complex pathophysiology of Alzheimer's disease (AD) has prompted researchers to develop multitarget-directed molecules to find an effective therapy against the disease. In this context, a novel series of N-(1-benzylpiperidin-4-yl)-5-arylisoxazole-3-ca

Design and synthesis of novel 5-arylisoxazole-1,3,4-thiadiazole hybrids as α-glucosidase inhibitors

Background: α-Glucosidase inhibitors have occupied a significant position in the treatment of type 2 diabetes. In this respect, the development of novel and efficient non-sugar-based inhibitors is in high demand. Objective: Design and synthesis of new 5-arylisoxazole-1,3,4-thiadiazole hybrids possessing α-glucosidase inhibitory activity were developed. Methods: Different derivatives were synthesized by the reaction of various 5-arylisoxazole-3-carboxylic acids and ethyl 2-((5-amino-1,3,4-thiadiazol-2-yl)thio)acetate. Finally, they were evalu-ated for their α-glucosidase inhibitory activity. Results: It was found that ethyl 2-((5-(5-(2-chlorophenyl)isoxazole-3-carboxamido)-1,3,4-thiadiazol-2-yl)thio)acetate (5j) was the most potent compound (IC50 = 180.1 μM) compared with acarbose as the reference drug (IC50 = 750.0 μM). Also, the kinetic study of 5j revealed a competitive inhibition and docking study results indicated desired interactions of that compound with amino acid residues located close to the active site of α-glucosidase. Conclusion: Good α-glucosidase inhibitory activity obtained by the title compounds introduced them as an efficient scaffold, which merits to be considered in anti-diabetic drug discovery developments.

Synthesis of 3-(1,2-dioxoethyl)- and 2,3-dicarbonyl-containing pyrroles

The transition metal-catalyzed reaction of 2H-azirines with 1,2,4-tricarbonyl compounds leads to 3-(1,2-dioxoethyl)- and 2,3-dicarbonyl-pyrrole derivatives, useful building blocks for the preparation of 3-heterocyclyl pyrroles and pyrroles fused with heterocycles. The influence of catalysts and the reaction conditions on the yields of pyrroles and the regioselectivity of the reaction were studied. Experimental and theoretical results suggest that the reaction proceeds via the formation of an intermediate azirine-metal complex and subsequent nucleophilic N-C3 bond cleavage.